Gilead Sciences
FDA Approves Yeztugo for HIV PrEP Lasting 6 Months
The FDA approved lenacapavir, an injectable HIV-1 capsid inhibitor, to be used as PrEP to reduce the risk of ...
JUNE 18, 2025
FDA Grants New Indication for Veklury to Treat COVID-19 in People With Hepatic Impairment
The FDA granted a supplemental new drug application for the use of remdesivir with no dose adjustments to treat ...
AUGUST 25, 2023
Gilead Subsidiary to Launch Generic HCV Drugs
The list price of authorized generics to reflect discounts in the system today.
SEPTEMBER 26, 2018
FDA Approves Expanded Indication for Truvada for PrEP for Adolescents
In the United States, adolescents and young adults aged 13 to 24 years comprised 21% of all new infections in 2016, ...
JULY 2, 2018
FDA Expands Indication for Truvada for PrEP Among Adolescents
The FDA granted a new indication for Gilead's Truvada to reduce the risk for sexually acquired HIV-1 in at-risk ...
MAY 15, 2018
Switching HIV Regimen Found Safe
Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...
MARCH 7, 2018
ViiV Files Suit Against Gilead Over HIV Drug Patents
ViiV claims bictegravir infringes on its patent covering dolutegravir and many other compounds that include ...
FEBRUARY 8, 2018
FDA Approves Biktarvy Triple Therapy for HIV Infection
The FDA approved Gilead's Biktarvy, a once-daily, single-tablet regimen for the treatment of HIV-1 infection.
FEBRUARY 8, 2018
HIV Drugs in the Pipeline: Expected Approvals for 2018
Pharmaceutical companies are looking at antiretroviral therapy regimens that are easier on patients with HIV.
FEBRUARY 7, 2018
Bictegravir-Containing Compound Found Noninferior in Phase 3 Trial
Bictegravir is a novel, potent integrase strand transfer inhibitor (INSTI), which features a high in vitro barrier ...
OCTOBER 10, 2017
FDA Approves Vosevi for Patients With Chronic HCV
The FDA has approved Vosevi, a single-tablet pangenotypic regimen for the treatment chronic HCV infection in adults ...
JULY 19, 2017
